DDInter1042 DDInter1921
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock. It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.
Vasopressin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Vasopressin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Vasopressin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin
Vasopressin may lead to a major life threatening interaction when taken with Fingolimod